This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simchen, C. Articles by Aust, G. Search for Related Content PubMed PubMed Citation Articles by Simchen, C. Articles by Aust, G.

Expression and Regulation of Regulated on Activation, Normal T Cells Expressed and Secreted in Thyroid Tissue of Patients with Graves’ Disease and Thyroid Autonomy and in Thyroid-Derived Cell Populations¹

Institute of Anatomy (C.S., D.S., G.A.) and Department of Surgery (M.S.), University of Leipzig; and Center of Environmental Research (I.L.), Halle-Leipzig GmbH, Leipzig, Germany

Address correspondence and requests for reprints to: Dr. Gabriela Aust, Institute of Anatomy, University of Leipzig, Liebigstr. 13, Leipzig 04103, Germany. E-mail: ausg{at}medizin.uni-leipzig.de

Thyroid glands affected by Graves’ disease (GD) show striking lymphocytic infiltration, mainly by CD45RO⁺ T cells. The mechanisms by which the various lymphocytic subsets are recruited and maintained in the thyroid are unknown. RANTES (regulated on activation, normal T cells expressed and secreted) in interaction with its receptors (CCR1, CCR3, CCR4 and CCR5) may be one of the favorite chemokines involved in the cell trafficking and maintenance.

RANTES messenger RNA (mRNA) was quantified in the thyroid tissue of 16 patients with GD and 7 patients with thyroid autonomy (TA), using competitive RT-PCR. We found a clear correlation between the RANTES mRNA level and 1) the degree of T-cell infiltration (r = 0.68), and 2) the level of serum antibodies to thyroid peroxidase (r = 0.76) in GD but not in TA patients. There was no difference between the autonomous nodules and the quiescent surrounding tissue in TA patients.

To define the cellular source of RANTES mRNA and protein, we examined various thyroid-derived cells. Lymphocytes showed a markedly higher basal RANTES mRNA and protein level (mean ± SEM; pg/mL, n = 3; 140 ± 30) than thyrocytes (12 ± 5) and fibroblasts (9 ± 2). Lymphocyte stimulation with PMA enhanced RANTES secretion significantly (4490 ± 200). Fibroblasts responded to stimulation with interleukin 1 (530 ± 220) and tumor necrosis factor (2780 ± 1790), whereas thyrocytes did not. However, some thyroid carcinoma cell lines showed very high basal and stimulated RANTES expression.

Lymphocytes expressed the mRNA of all chemokine receptors that bind RANTES. The number of CCR3⁺ and CCR5⁺ T cells was significantly higher in thyroid-derived leukocytes than in those in the peripheral blood stream.

We conclude that RANTES expression, mainly by lymphocytes, is perhaps involved in the maintenance of lymphocytic infiltration and, therefore, in the autoimmune responses in GD.

This article has been cited by other articles:

				H. Okamoto and N. Kamatani A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats Rheumatology, February 1, 2006; 45(2): 230 - 232. [Full Text] [PDF]

				A. P. Martin, E. C. Coronel, G.-i. Sano, S.-C. Chen, G. Vassileva, C. Canasto-Chibuque, J. D. Sedgwick, P. S. Frenette, M. Lipp, G. C. Furtado, et al. A Novel Model for Lymphocytic Infiltration of the Thyroid Gland Generated by Transgenic Expression of the CC Chemokine CCL21 J. Immunol., October 15, 2004; 173(8): 4791 - 4798. [Abstract] [Full Text] [PDF]

				B. S. Prabhakar, R. S. Bahn, and T. J. Smith Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy Endocr. Rev., December 1, 2003; 24(6): 802 - 835. [Abstract] [Full Text] [PDF]

				J. Pritchard, R. Han, N. Horst, W. W. Cruikshank, and T. J. Smith Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with Graves' Disease Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway J. Immunol., June 15, 2003; 170(12): 6348 - 6354. [Abstract] [Full Text] [PDF]

				P. Romagnani, M. Rotondi, E. Lazzeri, L. Lasagni, M. Francalanci, A. Buonamano, S. Milani, P. Vitti, L. Chiovato, M. Tonacchera, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the Thyroid and Increased Levels of IP-10/CXCL10 in the Serum of Patients with Recent-Onset Graves' Disease Am. J. Pathol., July 1, 2002; 161(1): 195 - 206. [Abstract] [Full Text] [PDF]

				J. Pritchard, N. Horst, W. Cruikshank, and T. J. Smith Igs from Patients with Graves' Disease Induce the Expression of T Cell Chemoattractants in Their Fibroblasts J. Immunol., January 15, 2002; 168(2): 942 - 950. [Abstract] [Full Text] [PDF]